These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19687473)

  • 1. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.
    Myöhänen TT; García-Horsman JA; Tenorio-Laranga J; Männistö PT
    J Histochem Cytochem; 2009 Sep; 57(9):831-48. PubMed ID: 19687473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hunting for peptide substrates of prolyl oligopeptidase: classical versus non-classical bioactive peptides.
    Tenorio-Laranga J; Männistö PT; García-Horsman JA
    CNS Neurol Disord Drug Targets; 2011 May; 10(3):319-26. PubMed ID: 21222622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of prolyl oligopeptidase with conventional neurotransmitters in the brain.
    Peltonen I; Myöhänen TT; Männistö PT
    CNS Neurol Disord Drug Targets; 2011 May; 10(3):311-8. PubMed ID: 21222629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of prolyl oligopeptidase in the mouse whole-body sections and peripheral tissues.
    Myöhänen TT; Venäläinen JI; García-Horsman JA; Piltonen M; Männistö PT
    Histochem Cell Biol; 2008 Nov; 130(5):993-1003. PubMed ID: 18618130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of immunoreactive prolyl oligopeptidase in human and rat brain.
    Myöhänen TT; Venäläinen JI; Tupala E; Garcia-Horsman JA; Miettinen R; Männistö PT
    Neurochem Res; 2007 Aug; 32(8):1365-74. PubMed ID: 17401647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular and subcellular distribution of rat brain prolyl oligopeptidase and its association with specific neuronal neurotransmitters.
    Myöhänen TT; Venäläinen JI; Garcia-Horsman JA; Piltonen M; Männistö PT
    J Comp Neurol; 2008 Apr; 507(5):1694-708. PubMed ID: 18253937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolyl oligopeptidase and its role in the organism: attention to the most promising and clinically relevant inhibitors.
    Babkova K; Korabecny J; Soukup O; Nepovimova E; Jun D; Kuca K
    Future Med Chem; 2017 Jun; 9(10):1015-1038. PubMed ID: 28632451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010.
    López A; Tarragó T; Giralt E
    Expert Opin Ther Pat; 2011 Jul; 21(7):1023-44. PubMed ID: 21539473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Localization of prolyl oligopeptidase in the thalamic and cortical projection neurons: a retrograde neurotracing study in the rat brain.
    Myöhänen TT; Kääriäinen TM; Jalkanen AJ; Piltonen M; Männistö PT
    Neurosci Lett; 2009 Jan; 450(2):201-5. PubMed ID: 19041368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spatial association of prolyl oligopeptidase, inositol 1,4,5-triphosphate type 1 receptor, substance P and its neurokinin-1 receptor in the rat brain: an immunohistochemical colocalization study.
    Myöhänen TT; Venäläinen JI; Garcia-Horsman JA; Männistö PT
    Neuroscience; 2008 Jun; 153(4):1177-89. PubMed ID: 18455882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of peptide-based prolyl oligopeptidase inhibitors--introduction of N-benzyloxycarbonyl-prolyl-3-fluoropyrrolidine as a lead in inhibitor design.
    Goossens F; Vanhoof G; De Meester I; Augustyns K; Borloo M; Tourwe D; Haemers A; Scharpé S
    Eur J Biochem; 1997 Nov; 250(1):177-83. PubMed ID: 9432007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders.
    Männisto PT; Venäläinen J; Jalkanen A; García-Horsman JA
    Drug News Perspect; 2007 Jun; 20(5):293-305. PubMed ID: 17878957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence resonance energy transfer (FRET) peptides and cycloretro-inverso peptides derived from bradykinin as substrates and inhibitors of prolyl oligopeptidase.
    Gorrão SS; Hemerly JP; Lima AR; Melo RL; Szeltner Z; Polgár L; Juliano MA; Juliano L
    Peptides; 2007 Nov; 28(11):2146-54. PubMed ID: 17904692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization and subcellular distribution of prolyl oligopeptidase in the mouse placenta.
    Matsubara S; Takahashi T; Kimura AP
    J Mol Histol; 2011 Jun; 42(3):251-64. PubMed ID: 21544597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.
    Tenorio-Laranga J; Coret-Ferrer F; Casanova-Estruch B; Burgal M; García-Horsman JA
    J Neuroinflammation; 2010 Apr; 7():23. PubMed ID: 20370893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboxypeptidase in prolyl oligopeptidase family: Unique enzyme activation and substrate-screening mechanisms.
    Yadav P; Goyal VD; Gaur NK; Kumar A; Gokhale SM; Jamdar SN; Makde RD
    J Biol Chem; 2019 Jan; 294(1):89-100. PubMed ID: 30409909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.
    Myöhänen TT; Tenorio-Laranga J; Jokinen B; Vázquez-Sánchez R; Moreno-Baylach MJ; García-Horsman JA; Männistö PT
    Br J Pharmacol; 2011 Aug; 163(8):1666-78. PubMed ID: 21133893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of the one-bead one-compound methodology for the design of prolyl oligopeptidase substrates.
    Comellas G; Kaczmarska Z; Tarragó T; Teixidó M; Giralt E
    PLoS One; 2009 Jul; 4(7):e6222. PubMed ID: 19593439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prolyl oligopeptidase inhibitor SUAM-14746 attenuates the proliferation of human breast cancer cell lines in vitro.
    Tanaka S; Suzuki K; Sakaguchi M
    Breast Cancer; 2017 Sep; 24(5):658-666. PubMed ID: 28070831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulating the selectivity of inhibitors for prolyl oligopeptidase inhibitors and fibroblast activation protein-α for different indications.
    Plescia J; Hédou D; Pousse ME; Labarre A; Dufresne C; Mittermaier A; Moitessier N
    Eur J Med Chem; 2022 Oct; 240():114543. PubMed ID: 35797897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.